Advancing Age Modulates Associations Between Cognitive Impairment and Brain Volumes in Early <scp>MS</scp>
INTRODUCTION: Cognitive impairment is common in multiple sclerosis (MS), but manifestations following the first demyelinating event are relatively unexplored. We investigated cross-sectional associations between magnetic resonance imaging (MRI)-derived brain volumes and the presence of cognitive impairment outcomes five years after the first presentation with a demyelinating event. METHODS: Comprehensive cognitive assessments were performed five years after a first clinical demyelinating presentation using the Minimal Assessment of Cognitive Function in MS (MACFIMS). Participant Z scores were calculated for each MACFIMS subtest using available regression-based normative data. Participants were defined as having a cognitive outcome if one or more MACFIMS subtests were below the applied cutoff of Z ≤ -1.50. Gray matter volumes (GMV) were calculated using 3D T1-weighted MRI sequences. Logistic regression models assessed associations between 5-year MRI measures and cognitive impairment (adjusting for total intracranial volume where relevant). RESULTS: decrease in GMV, 95% CI [1.00-1.13], p = 0.044). Among participants with a cognitive impairment outcome, there were significant associations between lower GMV and advancing age (p = 0.0095). Exploratory analysis of estimated marginal contrasts suggested that cognitive impairment outcomes were potentially associated with GMV above the age of 39 years (Z ≤ -1.50: p = 0.0476). DISCUSSION: Five years after a first demyelinating event, GMV volumes on MRI are significantly associated with the presence of cognitive outcomes, while advancing age also appears to be associated with GMV and cognitive outcomes.
Authors
- Michael A. Foster (ORCID: https://orcid.org/0000-0001-7201-7475)
- Indran Davagnanam (ORCID: https://orcid.org/0000-0002-0363-1911)
- Piriyankan Ananthavarathan (ORCID: https://orcid.org/0000-0003-4360-8991)
- Claudia A. M. Gandini Wheeler‐Kingshott (ORCID: https://orcid.org/0000-0002-4832-1300)
- Marios Yiannakas (ORCID: https://orcid.org/0000-0003-4986-446X)
- Sara Collorone (ORCID: https://orcid.org/0000-0003-1506-8983)
- Marco Pitteri (ORCID: https://orcid.org/0000-0001-8093-4548)
- Sara Salama (ORCID: https://orcid.org/0000-0003-2380-8152)
- Baris Kanber (ORCID: https://orcid.org/0000-0003-2443-8800)
- Elisa Colato (ORCID: https://orcid.org/0000-0002-4101-7058)
- Declan Chard (ORCID: https://orcid.org/0000-0003-3076-2682)
- Ferran Prados
- Olga Ciccarelli
- Ahmed Toosy
- Frederik Barkhof
Institutions
- Allen Institute for Brain Science (US)
- Universitat Oberta de Catalunya (ES)
- Queen Mary University of London (GB)
- University of Pavia (IT)
- Amsterdam Neuroscience (NL)
- UCL Biomedical Research Centre (GB)
- The London College (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
- Alexandria University (EG)
- University of Amsterdam (NL)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2026-04-10
- DOI
- https://doi.org/10.1002/acn3.70385
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Rosetrees Trust
- Medical Research Council
- UCLH Biomedical Research Centre